Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Ledermann

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
British Journal of Cancer|November 1, 1988
Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin AJ A Ledermann, R H Begent, K D Bagshawe, et al.
Gynecologic Oncology|December 3, 2005
Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG studyM L Harrison, P Hoskins, A du Bois, et al.
European Journal of Cancer & Clinical Oncology|June 1, 1989
EMOP/CA chemotherapy for the treatment of aggressive non-Hodgkin's lymphomasD B Smith, J A Ledermann, E Boesen, et al.
Lancet (London, England)|February 14, 2003
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trialT S Maughan, R D James, D J Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 4, 2001
High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)J A Ledermann, R Herd, D Maraninchi, et al.
British Journal of Cancer|June 1, 1992
Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma--implications for radioimmunotherapyG M Boxer, R H Begent, A M Kelly, et al.
Lancet (London, England)|June 6, 2002
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trialT S Maughan, R D James, D J Kerr, et al.
Gynecologic Oncology|April 1, 1991
Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiationJ A Ledermann, A J Dembo, J F Sturgeon, et al.
British Journal of Cancer|May 23, 2013
A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancerM McCormack, L Kadalayil, A Hackshaw, et al.
British Journal of Cancer|September 1, 1989
Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancerR H Begent, J A Ledermann, A J Green, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
British Journal of Cancer|November 1, 1988
Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin AJ A Ledermann, R H Begent, K D Bagshawe, et al.
Gynecologic Oncology|December 3, 2005
Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG studyM L Harrison, P Hoskins, A du Bois, et al.
European Journal of Cancer & Clinical Oncology|June 1, 1989
EMOP/CA chemotherapy for the treatment of aggressive non-Hodgkin's lymphomasD B Smith, J A Ledermann, E Boesen, et al.
Lancet (London, England)|February 14, 2003
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trialT S Maughan, R D James, D J Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 4, 2001
High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)J A Ledermann, R Herd, D Maraninchi, et al.
British Journal of Cancer|June 1, 1992
Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma--implications for radioimmunotherapyG M Boxer, R H Begent, A M Kelly, et al.
Lancet (London, England)|June 6, 2002
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trialT S Maughan, R D James, D J Kerr, et al.
Gynecologic Oncology|April 1, 1991
Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiationJ A Ledermann, A J Dembo, J F Sturgeon, et al.
British Journal of Cancer|May 23, 2013
A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancerM McCormack, L Kadalayil, A Hackshaw, et al.
British Journal of Cancer|September 1, 1989
Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancerR H Begent, J A Ledermann, A J Green, et al.
Pageof 7